Genprex, Inc.
Income Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $10.5M | $17.6M | $11.5M | $9.0M | $7.3M | $971.4K | $289.9K | $354.9K |
| SG&A Expense | $10.6M | $13.4M | $12.3M | $11.7M | $10.6M | $11.4M | $3.0M | $3.8M |
| Operating Income | $-21.2M | $-31.1M | $-23.8M | $-20.7M | $-18.0M | $-12.4M | $-3.3M | $-4.1M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | $38.0K | $1.9K | $0 |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $2.7K | $0 | $0 | — | — | — | — | — |
| Net Income | $-21.1M | $-30.9M | $-23.7M | $-20.7M | $-17.9M | $-12.4M | $-3.3M | $-4.1M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-22.24 | $-1.88 | $-1.65 | $-0.04 | $-0.04 | $-0.08 | $-0.02 | $-0.03 |
| EPS (Diluted) | — | — | — | $-0.04 | $-0.04 | $-0.08 | $-0.02 | $-0.03 |
| Shares Outstanding (Basic) | 961.7K | 16.4M | 14.4M | 565.2M | 517.4M | 182.9M | 140.7M | 136.4M |
| Shares Outstanding (Diluted) | 961.7K | 16.4M | 14.4M | 565.2M | 517.4M | 182.9M | 140.7M | 136.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |